IK
IKT.O
—
NASDAQ
Biotechnology
Ikt.O
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-29,0 %
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$2,21
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
IKT.O is a biotechnology company within the Health Care sector, currently operating with zero revenue and negative net income, relying on cash reserves to fund operations.
Business. IKT.O is a biotechnology company within the Health Care sector, currently operating with zero revenue and negative net income, relying on cash reserves to fund operations.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability→
-29,0 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to IKT.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
IKT.O is a biotechnology company within the Health Care sector, currently operating with zero revenue and negative net income, relying on cash reserves to fund operations.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
AI synthesis
GENERATED(a) Capital structure and liquidity are characterized by a net cash position, with total assets of $98.6 million and total liabilities of $3.7 million, resulting in a debt-to-equity ratio of 0.0. The company holds $97.5 million in cash and equivalents, which significantly exceeds its total liabilities, providing a strong liquidity buffer despite the risk assessment flagging liquidity as low, likely due to the absence of operating cash inflows.
(b) Profitability is negative, with a net income of -$27.5 million and an operating income of -$28.6 million. Return on equity stands at -29.01%, and return on assets is -27.91%, indicating that the company is currently destroying value relative to its capital base. Without cohort median data for comparison, these metrics reflect the typical burn profile of a pre-revenue biotechnology firm.
Key takeaways
- The company holds a strong net cash position of $97.5 million against $3.7 million in liabilities.
- Net income is -$27.5 million, with a negative return on equity of -29.01%.
- Revenue is $0.0, indicating a pre-commercial stage with no current sales.
- Dilution risk is assessed as low, with no immediate flags for share issuance.
- Classification confidence is low (0.20), reflecting uncertainty in the company's specific industry positioning.
Bull / Bear case
analysis pipeline— missing data
In focus — financials by report
Valuation
Market price
$2,17
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$94.9M
Net cashⓘ
$97.5M
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
-27.9%
ROEⓘ
-29.0%
Cash conversionⓘ
70.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution9 analysts
Strong buy4
Buy5
Hold0
Sell0
Strong sell0
12-month price target$6,00 · Median $6,00
Low $3,00High $8,00
Operating income · consensus-78,7M USD
EPS surprise
−14,7 %
reported vs consensus · miss
Revenue surprise
−100,0 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$3,00
Mean$6,00
Median$6,00
High$8,00
Spot$2,17
+176.5 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
ROE-29,0 %Above median
D/E0,00Above median
Cash Conv0,70Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 25 807 288 sh1 exercises · 9 grants10 insiders
- Director · Stock Option (Right to Buy) → Common StockDisposed 21 854 @ $1,26exercise · 2026-07-30
- 10% owner · Pre-Funded Warrant (Right to Buy) → Common StockAcquired 18 030 000 @ $0,00other · 2026-07-29
- Director · Stock Option (Right to Buy) → Common StockAcquired 155 000 @ $1,91grant · 2026-06-26
- Director · Stock Option (Right to Buy) → Common StockAcquired 155 000 @ $1,91grant · 2026-06-26
- Director · Stock Option (Right to Buy) → Common StockAcquired 155 000 @ $1,91grant · 2026-06-26
- Director · Stock Option (Right to Buy) → Common StockAcquired 155 000 @ $1,91grant · 2026-06-26
- Director · Stock Option (Right to Buy) → Common StockAcquired 155 000 @ $1,91grant · 2026-06-26
- Director · Stock Option (Right to Buy) → Common StockAcquired 155 000 @ $1,91grant · 2026-06-26
- Director, Chief Executive Officer · Stock Option (Right to Buy) → Common StockAcquired 4 982 706 @ $2,01grant · 2026-01-05
- Chief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 986 319 @ $2,01grant · 2026-01-05
- President & Head of R&D · Stock Option (Right to Buy) → Common StockAcquired 900 117 @ $2,01grant · 2026-01-05
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Return On Equitynet_income / total_equity
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Return On Assetsnet_income / total_assets
Source documents
- INHIBIKASE THERAPEUTICS, INC. Market data — financials · 2026-07-30
- reconciler_enqueue (reconciler) on IKT.O · 2026-07-30
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$9M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Milton H. WernerPresident, Chief Executive Officer, Director
Insider activity
Net buying1 buys · 0 sellsnet $3,0M6 insiders · last 365d
- Director · Common StockOther 21 854 @ $1,26$28K · 2026-07-30
- 10% owner · Common StockOther 18 030 000 · 2026-07-29
- Director · Common StockOther 19 089 · 2026-02-21
- Director · Common StockOther 255 299 · 2026-02-21
- President & Head of R&D · Common StockOther 338 282 · 2026-02-21
- 10% owner · Common StockBought 2 068 965 @ $1,45$3,0M · 2025-11-21
Short positioning
18.3Mshares short-6.0% vs prior
16.94days to cover
69.4%short of daily vol
8.4Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
IKT.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Evidence & claims
From filings & derived data- Operating income (annual): USD -51.97MUnknown
- EPS (diluted) (annual): USD-PER-SHARES -0Unknown
- Capex (annual): USD 13.4KUnknown
- Pre-tax income (annual): USD -48.26KUnknown
- Operating cash flow (annual): USD -27.79MUnknown
- Current assets (annual): USD 180.11MUnknown
- Shares outstanding (annual): 131.69MUnknown
- EPS (basic) (annual): USD-PER-SHARES -0Unknown
- Cash & equivalents (annual): USD 178.8MUnknown
- Current liabilities (annual): USD 8.3MUnknown
- Total liabilities (annual): USD 8.3MUnknown
- R&D expense (annual): USD 29.79MUnknown
- Total assets (annual): USD 181.2MUnknown
- Net income (annual): USD -48.26MUnknown
- Shareholders' equity (annual): USD 172.9MUnknown
- Capex (annual): USD 0Unknown
- Net income (annual): USD -27.52MUnknown
- Cash & equivalents (annual): USD 97.5MUnknown
- Shares outstanding (annual): 69.36MUnknown
- Revenue (annual): USD 0Unknown
- EPS (diluted) (annual): USD-PER-SHARES -1Unknown
- R&D expense (annual): USD 17.21MUnknown
- Total assets (annual): USD 98.6MUnknown
- Current liabilities (annual): USD 3.73MUnknown
Showing 24 of 31 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-30INSIDERBERMAN DENNIS N transacted 21.9k sh — Director ~$28k
2026-07-30INSIDERBERMAN DENNIS N disposed of 21.9k sh Stock Option (Right to Buy) — Director
2026-07-29INSIDERRA CAPITAL MANAGEMENT, L.P. transacted 18.03M sh — 10% owner
2026-07-29INSIDERRA CAPITAL MANAGEMENT, L.P. acquired 18.03M sh Pre-Funded Warrant (Right to Buy) — 10% owner
2026-06-26INSIDERBERMAN DENNIS N acquired 155.0k sh Stock Option (Right to Buy) — Director
2026-06-26INSIDERAurentz Vincent acquired 155.0k sh Stock Option (Right to Buy) — Director
2026-06-26INSIDERBellini Roberto acquired 155.0k sh Stock Option (Right to Buy) — Director
2026-06-26INSIDERKush Arvind acquired 155.0k sh Stock Option (Right to Buy) — Director
2026-06-26INSIDERCanner David acquired 155.0k sh Stock Option (Right to Buy) — Director
2026-06-26INSIDERMunshi Amit acquired 155.0k sh Stock Option (Right to Buy) — Director
2026-02-21 00:00 UTCINSIDER3 insider transactions — 2026-02
2026-02-21 00:00 UTCINSIDER3 insider transactions — 2026-02
2026-02-21INSIDERMunshi Amit transacted 19.1k sh — Director
2026-02-21INSIDERAurentz Vincent transacted 255.3k sh — Director
2026-02-21INSIDERCabell Christopher transacted 338.3k sh — President & Head of R&D
2026-01-05 00:00 UTCINSIDER3 insider transactions — 2026-01 3 derivative
2026-01-05 00:00 UTCINSIDER3 insider transactions — 2026-01 3 derivative
2026-01-05INSIDERIwicki Mark T acquired 4.98M sh Stock Option (Right to Buy) — Director, Chief Executive Officer
2026-01-05INSIDERCabell Christopher acquired 900.1k sh Stock Option (Right to Buy) — President & Head of R&D
2026-01-05INSIDERMcIntyre David acquired 986.3k sh Stock Option (Right to Buy) — Chief Financial Officer
2025-11-21 00:00 UTCINSIDER1 insider transaction — 2025-11 · net buy $3.0M
2025-11-21 00:00 UTCINSIDER1 insider transaction — 2025-11 · net buy $3.0M
2025-11-21INSIDERSands Capital Life Sciences Pulse Fund II, L.P. bought 2.07M sh — 10% owner ~$3.00M
2025-06-30 00:00 UTCINSIDER6 insider transactions — 2025-06 6 derivative
2025-06-30 00:00 UTCINSIDER6 insider transactions — 2025-06 6 derivative
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage